Wed, February 26, 2020

Raghuram Selvaraju Reiterated (BTAI) at Strong Buy with Increased Target to $95 on, Feb 26th, 2020

Raghuram Selvaraju of HC Wainwright & Co., Reiterated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Increased Target from $30 to $95 on, Feb 26th, 2020.

Raghuram has made no other calls on BTAI in the last 4 months.



There is 1 other peer that has a rating on BTAI. Out of the 1 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



This is the rating of the analyst that currently disagrees with Raghuram


  • Robyn Karnauskas of "SunTrust Robinson Humphrey" Maintained at Strong Buy with Increased Target to $150 on, Friday, February 14th, 2020


Similar Stocks and Investing Publications